Sunday, April 24, 2016
MammaPrint Shows Which Breast Cancer Patients Can Skip Chemo
A huge European trial has shown that the 70-gene assay MammaPrint can identify patients with early breast cancer who can safely skip adjuvant chemotherapy, even if they have clinical characteristics suggesting they are at high risk.
Results from this academic trial have been eagerly awaited since the trial began in 2007.
Known as MINDACT (Microarray for Node-Negative Disease May Avoid Chemotherapy Trial), the study involved 6693 patients across nine European countries.
It cost around €47 million (US$53 million), with funding provided by the European Organisation for Research and Treatment of Cancer (EORTC) Charitable Trust.
Outcome data, with a median follow-up of 5 years, were reported for the first time here at the American Association for Cancer Research 2016 Annual Meeting.
The women taking part in this trial had early-stage breast cancer and had undergone surgery. For the total trial population, the results show that using the genomic assay resulted in a 14% reduction in chemotherapy use versus assessment by clinical features of disease.
But the results were even more striking for a subgroup of patients, who were classed as high risk on clinical assessment. In these patients, use of the genomic assay is associated with a 46% reduction in chemotherapy prescription.
"The MINDACT trial results provide level 1A evidence that using MammaPrint could change clinical practice by substantially de-escalating the use of adjuvant chemotherapy and sparing many patients an aggressive treatment they will not benefit from," said principal investigator Martine Piccart, MD, PhD, head of the Department of Medicine at the Jules Bordet Institute in Brussels, and cofounder and chair of the Breast International Group (BIG).